TargetBeta
ENTPD1
ectonucleoside triphosphate diphosphohydrolase 1 · also ATP-DPH, NTPDase-1, ATPDase, SPG64 · CD molecules
3 programs in company-led studies act on ENTPD1, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014rule | Elpiscience (Suzhou) Biopharma | – | phase 2 | 32 running | – | NCIt |
| Anti-CD39 Monoclonal Antibody IPH5201 | Innate Pharma | – | phase 2 | 21 running | – | a judged reading |
| Anti-PD-1/Anti-CD39 Bispecific Antibody BNT317rule | BioNTech | – | phase 2 | 11 running | PDCD1 | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Desmoid Tumors, 1 program
- Neoplasm Metastasis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 28, 2027Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014 · Elpiscience (Suzhou) Biopharma · phase 2 · NCT05717348
- Jun 2027Anti-CD39 Monoclonal Antibody IPH5201 · Innate Pharma · phase 2 · NCT05742607
- Apr 2031Anti-PD-1/Anti-CD39 Bispecific Antibody BNT317 · BioNTech · phase 2 · NCT06750185
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.